This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
17 Jan 2012

Kedem Pharmaceuticals Starts Development of Sublingual Cancer Drug

Kedem says its sublingual formulation with taste masking features makes the drug acceptable and pleasant in taste for the children with chronic dosage requirements.

Canada's specialty pharmaceutical company Kedem Pharmaceuticals has started to develop Gleevec (imatinib), a drug for the treatment of several blood related cancers in children and adults.

 

In children the drug has demonstrated a powerful action against Chronic Myeloid Leukemia. The drug is administered orally and in children there is a significant issue in getting the drug swallowed, due to size of the pill and bad taste.

 

Kedem says its sublingual formulation with taste masking features makes the drug acceptable and pleasant in taste for the children with chronic dosage requirements.

 

The firm has several other drugs under development for fast and convenient delivery. These include drugs f

Related News